Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with BCG-naive, high-risk ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

An oncology nurse practitioner's transition from private practice to cancer research offers insights for nurses exploring new ...

Phase 1 data indicate invikafusp alfa's potential as a precision cancer immunotherapeutic in solid tumors that have ...

Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL ...

The SU2C-SARC032 study demonstrated that pembrolizumab combined with radiotherapy and surgery was well tolerated, with ...

Panelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated ...

The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL ...

Panelists discuss how to help patients weigh the risks and benefits of different treatment options for paroxysmal nocturnal hemoglobinuria (PNH), outlining tools and techniques used to ensure that ...

Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL ...